Report overview
The global Endothelin Antagonists Therapeutics market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Oral Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Endothelin Antagonists Therapeutics include Gilead Sciences, Inc, Sun Pharmaceutical Industries Ltd, Lupin, Zydus Group, Endo International plc, Mylan NV, Teva Pharmaceutical Industries Ltd, Sigmapharm Laboratories , LLC and Alembic Pharmaceuticals Limited, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Endothelin are the type of therapeutics that inhibits the action of endothelin and is thus effective for treating pulmonary arterial hypertension. This receptor, which plays a major role in regulating vascular tone, is found between the lumen and underlying media of the pulmonary vasculature. For patients suffering from the pulmonary hypertension, the body secrete high amount of endothelin that causes the blood vessels to be constricted and increase in the BP in the pulmonary arteries.
This report aims to provide a comprehensive presentation of the global market for Endothelin Antagonists Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endothelin Antagonists Therapeutics. This report contains market size and forecasts of Endothelin Antagonists Therapeutics in global, including the following market information:
Global Endothelin Antagonists Therapeutics Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global Endothelin Antagonists Therapeutics Market Sales, 2019-2024, 2025-2030, (K Units)
Global top five Endothelin Antagonists Therapeutics companies in 2023 (%)
We surveyed the Endothelin Antagonists Therapeutics manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Endothelin Antagonists Therapeutics Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Endothelin Antagonists Therapeutics Market Segment Percentages, by Type, 2023 (%)
Oral
Parenteral
Global Endothelin Antagonists Therapeutics Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Endothelin Antagonists Therapeutics Market Segment Percentages, by Application, 2023 (%)
Cardiovascular Diseases
Scleroderma
Other
Global Endothelin Antagonists Therapeutics Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Endothelin Antagonists Therapeutics Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Endothelin Antagonists Therapeutics revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies Endothelin Antagonists Therapeutics revenues share in global market, 2023 (%)
Key companies Endothelin Antagonists Therapeutics sales in global market, 2019-2024 (Estimated), (K Units)
Key companies Endothelin Antagonists Therapeutics sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead Sciences, Inc
Sun Pharmaceutical Industries Ltd
Lupin
Zydus Group
Endo International plc
Mylan NV
Teva Pharmaceutical Industries Ltd
Sigmapharm Laboratories , LLC
Alembic Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC
AstraZeneca
Johnsons & Johnsons Private limited
GSK Plc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Endothelin Antagonists Therapeutics, market overview.
Chapter 2: Global Endothelin Antagonists Therapeutics market size in revenue and volume.
Chapter 3: Detailed analysis of Endothelin Antagonists Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Endothelin Antagonists Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Endothelin Antagonists Therapeutics capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
